Oncology Learning NetworkPolatuzumab Vedotin in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: The GO29365 Study

Dr. Christopher Flowers, professor and chair of the Lymphoma Myeloma Department at the University of Texas MD Anderson Cancer Center, discusses the GO29365 study, which examined the combination of polatuzumab vedotin and bendamustine rituximab. The trial’s exploratory nature involved looking at the combination of polatuzumab vedotin with bendamustine and rituximab in a dose-finding component to determine the best dose to give to patients with follicular lymphoma and diffuse large B-cell lymphoma.